154 related articles for article (PubMed ID: 38074129)
1. Quantifying the impact of novel metastatic cancer therapies on health inequalities in survival outcomes.
Zebrowska K; Banuelos RC; Rizzo EJ; Belk KW; Schneider G; Degeling K
Front Pharmacol; 2023; 14():1249998. PubMed ID: 38074129
[No Abstract] [Full Text] [Related]
2. Overall survival of individuals with metastatic cancer in Sweden: a nationwide study.
Bütepage G; Carlqvist P; Jacob J; Toft Hornemann A; Vertuani S
BMC Public Health; 2022 Oct; 22(1):1913. PubMed ID: 36229841
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
[TBL] [Abstract][Full Text] [Related]
5. Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Shor A; Tremblay G
Cancer Manag Res; 2018; 10():1015-1025. PubMed ID: 29765249
[TBL] [Abstract][Full Text] [Related]
6. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review.
Shen C; Tannenbaum D; Horn R; Rogers J; Eng C; Zhou S; Johnson B; Kopetz S; Morris V; Overman M; Parseghian C; Chang GJ; Lopez-Olivo MA; Kanwal R; Ellis LM; Dasari A
JAMA Netw Open; 2022 May; 5(5):e2213588. PubMed ID: 35608860
[TBL] [Abstract][Full Text] [Related]
7. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
8. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
[TBL] [Abstract][Full Text] [Related]
9. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
10. Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.
Beauchemin C; Cooper D; Lapierre MÈ; Yelle L; Lachaine J
Onco Targets Ther; 2014; 7():1101-10. PubMed ID: 24971020
[TBL] [Abstract][Full Text] [Related]
11. The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.
Rossi A; Torri V; Garassino MC; Porcu L; Galetta D
Cancer Treat Rev; 2014 May; 40(4):485-94. PubMed ID: 24112813
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
[TBL] [Abstract][Full Text] [Related]
13. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Wu EQ
Exp Hematol Oncol; 2015; 4():31. PubMed ID: 26693096
[TBL] [Abstract][Full Text] [Related]
15. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
[TBL] [Abstract][Full Text] [Related]
16. Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers.
Karve SJ; Price GL; Davis KL; Pohl GM; Smyth EN; Bowman L
BMC Health Serv Res; 2014 Nov; 14():555. PubMed ID: 25392276
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
Sidhu R; Rong A; Dahlberg S
Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
[TBL] [Abstract][Full Text] [Related]
18. Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
Waliany S; Wakelee H; Ramchandran K; Das M; Huang J; Myall N; Li C; Pagtama J; Tisch AH; Neal JW
Clin Lung Cancer; 2022 Sep; 23(6):498-509. PubMed ID: 35753988
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
Chida K; Kotani D; Masuishi T; Kawakami T; Kawamoto Y; Kato K; Fushiki K; Sawada K; Kumanishi R; Shirasu H; Matsubara Y; Yuki S; Komatsu Y; Yamazaki K; Yoshino T
Oncologist; 2021 Oct; 26(10):845-853. PubMed ID: 34232546
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
Kazandjian D; Gong Y; Keegan P; Pazdur R; Blumenthal GM
JAMA Oncol; 2019 Oct; 5(10):1481-1485. PubMed ID: 31343662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]